Advertisement

Related Videos

Mark J. Ratain, MD: The Justification for a Randomized Trial of Low-Dose Ibrutinib

Victoria T. Brown, PharmD, BCOP, on Payer Intervention: The Example of Abiraterone

Sarah Yim, MD, on Clinical Development of Biosimilars: Lessons for Interventional Pharmacoeconomics

Welcome and Introduction to Vi3C

Daniel Goldstein, MD: Interventional Pharmacoeconomics - Why and How

Advertisement

Advertisement




Oct
19
Today In Oncology
Mocertatug Rezetecan (Mo-Rez) Shows Early Activity in Platinum-Resistant Ovarian and Endometrial Cancers
FDA Approves Dostarlimab for MSI-H/dMMR Locally Advanced Rectal Cancer
National Academy of Medicine Elects 100 New Members for 2026
Phase III VERIFY Trial Demonstrates Benefits of Rusfertide in Polycythemia Vera
ASH Issues New Recommendations for the Management of Myelofibrosis
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo